BACKGROUND: health-related quality of life is an important outcome measure in patients with colorectal cancer. Comparison with normative data has been increasingly undertaken to assess the additional impact of colorectal cancer on health-related quality of life.
eight studies (90.3%) compared the health-related quality of life of patients with normative data published elsewhere, whereas the remaining studies recruited a group of patients who had colorectal cancer and a group of control patients within the same studies. the european organisation for Research and treatment of Cancer Quality-of-life Questionnaire Core 30 was the most extensively used instrument (n = 16; 51.6%). eight studies (25.8%) were classified as "probably robust" for clinical decision making according to the efficace standard methodological checklist. our further quality assessment revealed the lack of score differences reported (61.3%), contemporary comparisons (36.7%), statistical significance tested (38.7%), and matching of control group (58.1%), possibly leading to inappropriate control groups for fair comparisons. LIMITATIONS: meta-analysis of differences between the 2 groups was not available. CONCLUSIONS: in general, one-fourth of comparative studies that evaluated health-related quality of life of patients who had colorectal cancer achieved high quality in reporting characteristics and methodological details. future studies are encouraged to undertake healthrelated quality-of-life measurement and adhere to a methodological checklist in comparison with controls. C olorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer deaths worldwide. 1 Because of the emerging treatment therapies for CRC, a significant group of CRC patients survived with prolonged life expectancy, 2 whose health-related quality-of-life (hRQol) outcomes were of interest to the clinicians and decision makers for the development of optimal treatment strategies inducing the preservation of hRQol. 3 furthermore, the importance of incorporating hRQol assessments in oncological clinical trials has been well recognized in comparative effectiveness research to aid in clinical practice and decision making. 4 Comparisons with published normative data have been undertaken to assess the additional impact of cancer and cancer treatment on hRQol scores, 5, 6 given the coexistence of chronic conditions likely affecting hRQol. such comparison is important because norm-based comparison allows for quantifying the extent of departures from the norm and facilitates interpretation of the clinical importance of hRQol scores. With reference to countryspecific normative data, hRQol data of CRC patients were increasingly compared with the hRQol data of the non-CRC control group as an indication of the hRQol restriction in CRC patients. most studies reported hRQol outcomes comparisons between the CRC and non-CRC control groups with reference to country-specific normative data. findings from a systematic review of 10 hRQol studies among long-term CRC survivors 7 concluded that CRC patients appeared to have a comparable psychological aspect of hRQol but a slightly lower physical aspect of hRQol than available normative data. it is noteworthy that the methodological standards and normative data for such hRQol comparisons varied across studies, 7, 8 hampering the value and importance of clinical interpretation.
Despite numerous studies available over the past 2 decades, there has been an increased concern regarding the methodological and reporting quality of hRQol studies in clinical trials involving CRC patients. an 11-item checklist proposed by efficace et al 9 has been widely applicable to evaluate the quality of hRQol reporting in oncological clinical trials. Particularly for CRC studies, systematic review 10 identified the methodological shortcomings of 31 randomized controlled trials measuring hRQol as primary or secondary end points, particularly addressing the lack of baseline compliance and missing data reported in a majority of studies. however, evidence on detailed methodological critique of quality and reporting characteristics of comparative studies that assessed hRQol differences between groups is limited. the purpose of this study was to conduct a systematic review of the methodological quality of comparative studies that compared hRQol between CRC and control groups by either generic or cancer-specific instruments, including assessment of the extent to which the specific domains of hRQol of CRC patients were significantly different from those of healthy controls.
METHODS

Search Engine and Strategy
systematic literature search was conducted on may 2014 in databases of Pubmed, Web of science using the Web of Knowledge platform, embase, and medline using the oViD searching platform, to identify studies that investigated the hRQol of patients who had colorectal neoplasms. the medical subject heading "quality of life" was combined with "colon neoplasm," "colon cancer," "rectal cancer," "rectal neoplasm," and "colorectal cancer." studies were limited to the english language and the years between January 1985 and march 2014. electronic search strategy in each electronic database is shown in appendix 1, and has been adopted in 1 previous systematic review. 11 no additional hand searching was done.
after the initial check for duplicated articles, the titles and abstracts of remaining articles were screened to rule out the introductions, editorials, letters, commentaries, study protocols, case reports, pure literature reviews and meta-analyses, conference proceedings, and past and current clinical guidelines and recommendations. selected articles were further screened with full texts. the eligibility criteria of studies were 1) to involve original articles, 2) to measure hRQol by using standardized instruments with items rating on point likert scales or on linear analogue scales, and 3) to compare at least 1 hRQol outcome between CRC patients and the general population/healthy controls. articles without available full text were excluded. articles were also excluded if no abstract and full text were available. When there were multiple reports of studies using the same sample, the most updated publication of the study was included.
two reviewers (C.K.h.W. and J.C.) independently screened the eligibility criteria of study titles, abstracts, and selected full texts of the studies retrieved by the literature search. thus, assessment of the quality in eligible studies was performed by 2 reviewers independently (C.K.h.W. and J.C.). Disagreements regarding the procedures of database search, study selection and eligibility were resolved by discussion.
Data
Extraction study characteristics including first author, year of publication, country of origin, study design, population, sample size, demographics of CRC patients and non-CRC control population, response rate, hRQol instruments, and hRQol outcomes of eligible studies were independently extracted by 2 reviewers (C.K.h.W. and J.C.).
Methodological and Reporting Quality Assessment
each of the studies was evaluated by using the ''minimum standard Checklist for evaluating hRQol outcomes in Cancer Clinical trials" 12 to access the hRQol trial quality. the checklist consisted of 11 items grouped into 4 key categories related to the hRQol assessment: conceptual, measurement, methodology, and interpretation. this 11item checklist was designed to have a dichotomous answer (yes/no): 1 mark for "yes" (giving a score of 1) and 0 mark for "no" (giving a score of 0). each study was classified into one of the following 3 descriptive categories: "very limited" (with a score between 0 and 4), "limited" (with a score between 5 and 7), and "probably robust" (with a score between 8 and 11 and with 3 mandatory items of the checklist: baseline compliance, psychometric properties reported, and missing data documented). 12 as a result, studies having a score of 8 or above but not possessing those 3 mandatory items were regarded as "limited." this checklist provided a general guideline for addressing the basic and essential issues a study should possess to have convincing and significant outcomes in the assessment methodology.
Besides, authors (C.K.h.W. and J.C.) reached consensus on which further quality assessment should be evaluated in comparative studies reporting hRQol differences between CRC patients and controls. a further quality assessment consists of 5 predefined quality assessment criteria: 1) comparison with their populations: CRC and control groups should come from an identical source population; 2) contemporary comparisons: both groups should be enrolled during the same time period of within 5 years;
3) general population: as source of the comparison group; 4) matched comparison group: minimizing confounding factors that could introduce bias of differences between the CRC and control groups; and 5) reporting and presenting results: results of CRC group, comparison group, and the difference between groups should be reported and the statistical significance between groups should be tested. for each study, every single quality criterion was rated as "Yes" or "no" if the criterion was met or not. figure 1 lists the process of literature identification, screening for eligibility, and selection of studies during the literature search presented in a Preferred Reporting items for systematic Reviews and meta-analyses (PRisma) flow diagram. the literature search was completed in June 2014 and identified a total of 7553 potentially relevant studies (Pubmed: 1349; Web of science: 2318; medline: 1735; and embase: 2151) that met the searching criteria in 4 bibliographic databases. abstract screening removed the duplicated articles (n = 3332), nonoriginal articles (n = 1439), and articles not related to CRC patients (n = 1346), and noncomparative studies (n = 1401). the full-text content of 35 studies was reviewed for eligibility. to exclude ineligible studies because of the use of a nonstandardized hRQol instrument (n = 1) and no general population/healthy controls for comparisons (n = 3), the full-text articles of all eligible studies (n = 31) were included. the earliest comparative study that assessed the difference in hRQol between CRC patients and controls was published in 2003. 17, 24, 25, 27 , and scandinavia (n = 3; 9.7%). the remainder originated from the united states (n = 5; 16.1%), 6,22,37-39 australia (n = 2; 6.5%), 40, 41 and asia (n = 1; 3.2%). 42 twenty-eight studies (90.3%) collected a sample of CRC patients and compared them with normative data published elsewhere, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] whereas the remaining minority recruited a group of CRC patients and a group of healthy control subjects within the same studies. a summary of these 31 comparative studies is presented in table 1.  table 2 shows the general characteristics and available normative data of the standardized validated hRQol instruments identified in comparative studies. the european organisation for Research and treatment of Cancer Quality-of-life Questionnaire Core 30 (eoRtC QlQ-C30) was the most extensively used hRQol instrument, which was used in over half (n = 16; 51.6%) of the studies. [13] [14] [15] [18] [19] [20] [21] [22] [24] [25] [26] 31, 32, [34] [35] [36] the european organisation for Research and treatment of Cancer Colorectal Cancer specific Quality-of-life Questionnaire module (eoRtC QlQ-CR38) was also applied in 13 (43.3%) studies. 14, 16, 19, [22] [23] [24] [25] [26] [29] [30] [31] [32] 35 six non-cancer-specific hRQol instruments such as euroQol 5-dimension, sf-36, sf-12, Sf-6D, Psychological General Well-Being index (PGWBi), hospital anxiety and Depression scale (haDs) were identified for hRQol comparisons in comparative studies. the aforementioned 8 instruments were standardized and validated hRQol instruments, for which translations are available in many languages. two studies 34, 42 reported the hRQol measured by the functional assessment of Cancer therapy-colorectal instrument, but normative values of the functional assessment of Cancer therapycolorectal instrument were not available for comparisons. in table 3 , the results of the hRQol assessment methodology and methods of analysis are summarized in 4 major categories: conceptual, measurement, methodology, and interpretation, according to the "minimum standard Checklist for evaluating hRQol outcomes in Cancer Clinical trials." 12 methodological limitations were identified in several aspects of the overall process of hRQol assessment, particularly in terms of the conceptual criteria, methodology, and interpretation.
RESULTS
Overview of HRQOL Assessment Methodology and Methods of Analysis
Conceptual
in the conceptual criteria, our review doscerned the poor reporting of details about the a priori hypothesis and rationale for selecting a specific hRQol measure and instrument administration. only 1 (3.2%) of 31 studies had an a priori hypothesis stated 29 the studies provided a rationale for selecting the specific hRQol instrument. 13, 14, 17, 19, 20, 22, 26, 27, 32, 34, 40 Measurement in terms of measurement, although 38.7% (n = 12) of the reports did not verify the cultural validity of the study, 13 
Overview of HRQOL Trial Quality and Treatment Recommendation on Patient HRQOL
Based on the minimum standard checklist score in table 4, only 1 study (3.2%) was classified as very limited 35 and 71.0% (n = 22) were classified as limited, 6,15,17,18,21,23-25,27-33,36-42 whereas 8 studies (25.8%) were classified as "probably robust" for clinical decision making. 13, 14, 16, 19, 20, 22, 26, 34 these studies demonstrated excellent examples for the implementation of hRQol assessment of patients to thoroughly evaluate the overall effectiveness of treatment. English German, 43 Norway, 44 Netherlands, 45 Austria, 46 Sweden, 47 austria, 46 sweden, 47 and france. 15 Published normative data of eoRtC QlQ-C30 were available in the general adult population after matching for age and sex 15, 18, 24, 25, 31, 36 and different aspects such as CRC patients after diagnosis, [13] [14] [15] 20 CRC patients after surgery, 21, 31, 32, 34, 36 patients with rectal cancer following diagnosis, 19, 26 and patients with rectal cancer following surgery. 22, 24, 25, 31, 35 moreover, reference data from the eoRtC QlQ-C30 in a sample of 3000 adults from a norwegian general population provided comparison with patients with rectal cancer during radiotherapy 19 or survivors of rectal cancer. 26 Dutch normative data of eoRtC QlQ-C30 in age-and sex-matched general population were compared with random samples of the eindhoven Cancer Registry. 31 in addition, norms for another cancer-specific hRQol instrument eoRtC QlQ-CR38, which was also found in 5 (16.1%) studies, 16, 23, [29] [30] [31] have been obtained from the general population in the netherlands 45 for comparisons. only 1 study recruited the healthy controls through random sampling in the general population 32 and tested the control group against the CRC patients after surgery.
Further Quality Assessment
norms for generic hRQol instruments are also available in multiple countries. 45, [48] [49] [50] [51] [52] [53] [54] [55] General population norms for the sf-36 health survey were compared with hRQol of CRC patients in the netherlands, 23, 29, 30 france, 15 australia, 41 italy, 17 finland, 33 and the united states. 6, 37, 38 Comparisons with general population norms for sf-12 were used in the united Kingdom, 34 australia 40 and hong Kong. 42 the haDs score of CRC patients were compared with the uK 50 and Dutch 28 general population. the PGWBi, euroQoL 5-dimension, and Sf-6D scores were used in 1 study in italy, 27 in the united Kingdom, and in the united states. 39 in comparison with the normative data from the general population of italy, 24, 25 Germany, 13, 14, 21 norway, 19 austria, 18 and Poland, 35 CRC patients had worse scores in most of functioning and symptom scales measured by eoRtC QlQ-C30. Cancer survivors had significantly lower physical component summary (PCs) scores than the australian general population 41 and the uK population with an age interval of 65 to 74 years. 34 inconsistent results 14 Yes Yes German general population No Nil Jansen 20 Yes No German general population No Nil Kopp 21 Yes Yes German general population No Nil Rauch 26 No No Norwegian and German general populations No Nil Neuman 22 No No German general population No Nil Pucciarell 25 No No German general population Yes Age-and sex-matching Zajac 35 No No German general population No Nil Pucciarelli 24 No No German general population Yes Age-and sex-matching Guren 19 Yes Yes Norwegian general population No Nil Thong 30 Yes Yes Dutch general population Yes Age-and sex-matching Thong 29 Yes Yes Dutch general population Yes Age-and sex-matching Austin 41 Yes 18 Yes Yes Austrian general population Yes Age-and sex-matching Trninic 32 Yes Yes Healthy population No Nil Caravati-Jouvenceaux 15 Yes Yes French general population Yes Age-, sex-and residence area-matching Gall 40 Yes Yes Australian general population No Nil Reeve 6 Yes Yes Individuals without cancer Yes Propensity score matching Den Oudsten 16 Yes Yes Dutch general population Yes Age-and sex-matching Thong 28 Yes Yes Dutch general population Yes Age-and sex-matching Orsini 23 Yes Yes Dutch general population Yes Age-and sex-matching Traa 31 Yes Yes Dutch general population Yes Age-and sex-matching Wong 42 Yes Yes Hong Kong general population Yes Age-and sex-matching Pollack 36 Yes Yes Sweden general population Yes Age-matching were observed in the us population when the generic and cancer-specific hRQol of the general population were similar to that of CRC patients, 22, 37, 38 but the sf-6D score norms ranging from 0.76 to 0.80 were higher than that with 0.69 for permanent stoma and 0.73 for anastomoses among CRC survivors. 39 Conversely, older CRC survivors reported better than the general population in Germany 20 and finland, 33 but younger survivors conversely reported worse. the hRQol scores of rectal cancer survivors who have completed the treatment regimen for more than 2 or 10 years were higher than that of the general population from france 26 and the netherlands. 29, 30 in another french population-based study, cancer survivors reported worse social functioning and more diarrhea symptoms at 5 years after diagnosis than the healthy control group. 15 healthy controls had significantly better results in functional and symptom scales of eoRtC QlQ-C30 than patients with CRC in Bosnia 32 and austria. 18 for eoRtC QlQ-CR38, there were almost no comparisons in those studies between the CRC group and control group, with the exception of 1 study. 32 CRC patients had worse scores in most of scales measured by eoRtC QlQ-CR38 than healthy controls. for sf-12, CRC patients had lower PCs but higher mental component summary scores in comparison with the norms of their respective countries in australia, the united Kingdom, and hong Kong. 34, 40, 42 for sf-36, italian patients with colorectal cancer had lower hRQol in reference to bodily pain, social functioning, and general health measured than that of the general population. 17 australian patients with rectal cancer had a lower PCs than, but a similar mental component summary to, that of general population, 41 whereas there were no big differences between the CRC survivors group and control group for the american female patients. 37, 38 for PGWBi, population-based reference data were collected in the italian general population as control group to compare with rectal cancer survivors who reported better scores on all PGWBi scales, with the exception of the selfcontrol scale. 27 DISCUSSIONS in this systematic review, we summarized and appraised the methodological and reporting quality of 31 studies that compared the hRQol between CRC patients and controls, which provided information on the additional impact of CRC on hRQol. the results have shown that there were only 8 studies (25.8%) considered as "probably robust" regarding the methodological and reporting quality of hRQol comparisons, hampering informing clinical practice and decision making.
this review detected several drawbacks of current studies reporting hRQol comparisons between CRC and control groups. first, there is a disparity of the hRQol instrument used. high-quality studies were more likely to measure hRQol using the eoRtC QlQ-C30 instrument in conjunction with eoRtC QlQ-CR38 instrument, whereas several studies only used generic hRQol instruments to compare the hRQol between the CRC and control groups (references only use generic hRQol). it is more informative to combine both generic and specific hRQol instruments in comparing the hRQol between the CRC and control groups because generic instruments of hRQol can be used to compare hRQol over a broad spectrum of diseases, as well as the general population, and were more responsive to detect changes in social domain than colorectal-specific hRQol instruments. 56 however, only 5 studies used both generic and specific hRQol instruments based on the results of our systematic review. second, almost 40% of the included studies used an hRQol instrument that had not been culturally verified. it is important to choose a well-tested hRQol measure in certain cultures, because it is culture dependent. 57 this review underlined the importance of establishing an appropriate control group for fair comparison. of the 31 included studies, only 3 studies recruited the CRC patients and healthy controls within the same studies. 15, 18, 32 some studies even compare reference data from different populations, which may not accurately reflect the additional impact of CRC on hRQol compared with the controls in the same country. Because hRQol is always dependent on age and sex, comparison between CRC patients and the control group should match with age and sex, or adjust for multiple covariates by using a propensity score. however, over 60% of the studies did not perform a matching strategy to identify the controls. another issue of the control group is relevant to the noncontemporary comparison, which means that the difference of the recruitment period between CRC group and the control group is more than 5 years. statistical significance is useful in interpreting the data to account for fluctuations by chance, and thus does not necessarily imply clinical significance. a difference that is statistically different may have little or even no importance in the realm of health care and health decision making. in this systematic review, 10 comparative studies (32.3%) did not provide the clinical significance for analysis, 17, 23, [31] [32] [33] [34] 36, 37, 40, 42 which may hamper the clinical meaningfulness based on the results. Clinical significance of hRQol scores was determined by 2 main approaches. for those studies interpreting whether changes were considered as clinically significant, a half-standard deviation approach, 58 corresponding to Cohen medium effect size, was adopted 6, 16, [28] [29] [30] for detecting clinically important differences in hRQol scores. in comparative studies [13] [14] [15] [18] [19] [20] 22, 24, 25 administering eoRtC instruments, scores difference of at least 10 absolute points is interpreted as a clinically important difference according to osoba et al. 59 a priori hypotheses and rationales for the selection a hRQol instrument are lacking in most of the included studies. Because the a priori hypothesis is the key prerequisite for deciding which hRQol instrument is to be used, the lack of such information may lead to spurious positive results because of the multiple tests in comparing different hRQol domains between the CRC and control groups.
limitations of this review should be noted. first, methodological quality assessment relied on the information reported in published articles which may be shortened subject based on requests by editors and reviewers. Results of published articles may be partially reported. furthermore, a meta-analysis of differences between the 2 groups was not available based on hRQol point estimate reported in published articles.
CONCLUSIONS
this review showed that one-fourth of comparative studies generally achieved high quality in reporting characteristics and methodological details. hRQol is increasingly used to complement the outcomes of CRC patients, but our systematic review noted that only 8 of 31 studies met the methodological criteria as probably robust for clinical decision making according to the minimum standard Checklist for evaluating hRQol outcomes in Cancer Clinical trials. Researchers should pay careful attention to the hRQol instrument standardization with an a priori hypothesis and choose a comparable control group with a similar cultural background recruited at a similar time point. future studies investigating the impact of CRC on hRQol are encouraged to undertake hRQol measurement and adhere to a methodological checklist and further predefined assessment criteria.
